Jasper Therapeutics develops briquilimab, a targeted anti c-Kit monoclonal antibody that depletes mast cells and diseased stem cells to enhance the safety and efficacy of hematopoietic stem cell transplants. The company focuses on treating chronic conditions such as asthma and chronic urticaria, as well as rare genetic disorders like sickle cell disease and severe combined immunodeficiency.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for chronic immunological and inflammatory diseases, as well as conditioning regimens for hematopoietic stem cell transplants, often lack the desired safety and efficacy profiles, leading to suboptimal outcomes for patients. Mast cell-driven diseases and the need for safer stem cell therapies represent significant unmet medical needs.
Solution
Jasper Therapeutics is developing Briquilimab, a targeted anti-KIT monoclonal antibody, to address these challenges. Briquilimab is designed to selectively deplete mast cells and diseased stem cells, offering a novel approach to treating chronic immunological and inflammatory conditions, such as chronic urticaria and asthma. Additionally, Briquilimab is being investigated as a conditioning agent for hematopoietic stem cell transplants in rare genetic disorders like sickle cell disease, Fanconi anemia, and severe combined immunodeficiency, aiming to improve the safety and effectiveness of these potentially curative therapies. By precisely targeting KIT, a receptor tyrosine kinase expressed on mast cells and hematopoietic stem cells, Briquilimab seeks to mitigate off-target effects associated with traditional treatments.
Target Audience
The primary target audience includes patients suffering from chronic mast cell-driven diseases, individuals requiring hematopoietic stem cell transplants, and clinicians specializing in immunology, hematology, and genetic disorders.
Features
- Targeted anti-KIT monoclonal antibody for selective mast cell and diseased stem cell depletion.
- Potential therapeutic for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma.
- Investigational conditioning agent for hematopoietic stem cell transplants in rare genetic disorders.
- Aims to enhance the safety and efficacy of stem cell gene therapies.